Асосий контентга ўтиш
AkademIndex

Маҳсулотлар

Ишлаб чиқувчилар учун

AkademBaseЭкотизим учун очиқ API
← Ишга қайтиш

Ушбу иш иқтибос қилган ишлар

206 та иш

Иш: Advances in monitoring and therapy from minimal residual disease to CAR-T cells in multiple myeloma and precursor disorders

  1. High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma

    Luca Bertamini, Stefania Oliva, Delia Rota‐Scalabrini +26

    Мақола20222 иқтибос
    ABI

  2. Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma

    Juan‐José Garcés, María‐Teresa Cedena, Noemí Puig +25

    Мақола20222 иқтибос
    ABI

  3. More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia–Like Multiple Myeloma

    Tomáš Jelı́nek, Renata Bezděková, David Žihala +27

    Мақола20222 иқтибос
    ABI

  4. Chromosomal defects in multiple myeloma

    Sarah E. Clarke, Kathryn A. Fuller, Wendy N. Erber

    Шарҳ мақола20242 иқтибос
    ABI

  5. Genomic Classification and Individualized Prognosis in Multiple Myeloma

    Francesco Maura, Arjun Raj Rajanna, Bachisio Ziccheddu +34

    Мақола20242 иқтибос
    ABI

  6. The Burgeoning Significance of Liquid-Liquid Phase Separation in the Pathogenesis and Therapeutics of Cancers

    Wei-Xin Xu, Qiang Qu, Hai-Hui Zhuang +5

    Мақола20242 иқтибос
    ABI

  7. Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages

    Yan Cheng, Fumou Sun, Daisy Alapat +17

    Мақола20242 иқтибос
    ABI

  8. Diagnosis and Management of Monoclonal Gammopathy of Undetermined Significance

    Yuxin Liu, Anna L. Parks

    Шарҳ мақола20252 иқтибос
    ABI

  9. International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma

    Hervé Avet‐Loiseau, Faith E. Davies, Mehmet Samur +43

    Мақола20252 иқтибос
    ABI

  10. Machine Learning-Based Predictive Model for Risk Stratification of Multiple Myeloma from Monoclonal Gammopathy of Undetermined Significance

    Amparo Santamaría, Marcos Alfaro, Cristina Antón Rodríguez +5

    Мақола20252 иқтибос
    ABI

  11. Current updates on generations, approvals, and clinical trials of CAR T-cell therapy

    Tadesse Asmamaw Dejenie, Markeshaw Tiruneh G Medhin, Gashaw Dessie Terefe +3

    Мақола20222 иқтибос
    ABI

  12. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma

    Juan Flores‐Montero, Luzalba Sanoja-Flores, Bruno Paiva +30

    Мақола20172 иқтибос
    ABI

  13. Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report

    David Murray, Noemí Puig, Sigurður Y. Kristinsson +10

    Мақола20212 иқтибос
    ABI

  14. Interplay between proteasome inhibitors and NF-κB pathway in leukemia and lymphoma: a comprehensive review on challenges ahead of proteasome inhibitors

    Mahdi Pakjoo, Seyed Esmaeil Ahmadi, Mohammad Zahedi +4

    Шарҳ мақола20242 иқтибос
    ABI

  15. Preliminary screening of biomarkers and drug candidates in a mouse model of β-thalassemia based on quasi-targeted metabolomics

    Xianfeng Guo, Xuchao Zhang, Min Li +3

    Мақола20242 иқтибос
    ABI

  16. Addressing graft-versus-host disease in allogeneic cell-based immunotherapy for cancer

    Zibai Lyu, Siyue Niu, Ying Fang +3

    Шарҳ мақола20252 иқтибос
    ABI

  17. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI

  18. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI

  19. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI

  20. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI

  21. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI

  22. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI

  23. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI

  24. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI

  25. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI